Her Yeng F, Kubrova Eva, Martinez Alvarez Gabriel A, D'Souza Ryan S
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Hospital, Rochester, MN, 55905, USA.
Department of Physical Medicine and Rehabilitation, Mayo Clinic Hospital, Rochester, MN, 55905, USA.
J Pain Res. 2022 Oct 20;15:3299-3318. doi: 10.2147/JPR.S373345. eCollection 2022.
Pain originating from the intervertebral disc (discogenic pain) is a prevalent manifestation of low back pain and is often challenging to treat. Of recent interest, regenerative medicine options with injectable biologics have been trialed in discogenic pain and a wide variety of other painful musculoskeletal conditions. In particular, the role of bone marrow aspirate concentrate (BMAC) and culture-expanded bone marrow derived mesenchymal stromal cells (BM-MSCs) in treating discogenic pain remains unclear. The primary objective of this systematic review was to appraise the evidence of intradiscal injection with BMAC and culture-expanded BM-MSCs in alleviating pain intensity from discogenic pain. Secondary outcomes included changes in physical function after intradiscal injection, correlation between stromal cell count and pain intensity, and anatomical changes of the disc assessed by radiographic imaging after intradiscal injection. Overall, 16 studies consisting of 607 participants were included in qualitative synthesis without pooling. Our synthesis revealed that generally intradiscal autologous or allogeneic BMAC and culture-expanded BM-MSCs improved discogenic pain compared to baseline. Intradiscal injection was also associated with improvements in physical functioning and positive anatomical changes on spine magnetic resonance imaging (improved disc height, disc water content, Pfirrmann grading) although anatomical findings were inconsistent across studies. However, the overall GRADEscore for this study was very low due to heterogeneity and poor generalizability. There were no serious adverse events reported post intradiscal injection except for a case of discitis.
源自椎间盘的疼痛(椎间盘源性疼痛)是腰痛的常见表现,且治疗往往具有挑战性。最近,可注射生物制剂的再生医学疗法已在椎间盘源性疼痛及多种其他疼痛性肌肉骨骼疾病中进行了试验。特别是,骨髓抽吸浓缩物(BMAC)和培养扩增的骨髓间充质基质细胞(BM-MSCs)在治疗椎间盘源性疼痛中的作用仍不明确。本系统评价的主要目的是评估椎间盘内注射BMAC和培养扩增的BM-MSCs减轻椎间盘源性疼痛强度的证据。次要结局包括椎间盘内注射后身体功能的变化、基质细胞计数与疼痛强度之间的相关性,以及椎间盘内注射后通过影像学评估的椎间盘解剖学变化。总体而言,16项研究共607名参与者纳入了定性合成分析,未进行合并分析。我们的综合分析表明,与基线相比,椎间盘内自体或异体BMAC以及培养扩增的BM-MSCs通常可改善椎间盘源性疼痛。椎间盘内注射还与身体功能的改善以及脊柱磁共振成像上的积极解剖学变化相关(椎间盘高度增加、椎间盘含水量增加、Pfirrmann分级改善),尽管不同研究的解剖学结果并不一致。然而,由于异质性和普遍适用性差,本研究的总体GRADE评分非常低。除了1例椎间盘炎外,椎间盘内注射后未报告严重不良事件。